Top January 2023 FDA Approvals
January FDA approvals include treatments for mood disorders, pertussis in infants, Alzheimer disease, and type 2 diabetes.
January FDA approvals include treatments for mood disorders, pertussis in infants, Alzheimer disease, and type 2 diabetes.
A woman is evaluated by psychiatry on postpartum day 2 after staff noticed her talking to the mirror in her room and not showing affection to her newborn child. Case shows ethical decisions made when managing mental illness during pregnancy.
The approval was based on data from adequate and well-controlled studies with risperidone long-acting injection (intramuscular).
Three clusters detected corresponding to positive symptoms, negative symptoms and work functioning, and functional domains.
Investigators searched PubMed, Cochrane Library, Medline, Embase, CNKI, Weipu, and Wanfang databases for eligible studies through March 2022.
Genetic liability to ADHD, schizophrenia linked to pregnancy-related factors thought to be associated with these conditions.
To better identify and categorize symptoms, researchers developed a machine learning model to “redraw boundaries” within early psychosis.
Researchers sought to find mechanisms of impaired impulsivity control in patients with BD responding to emotion and compare them to patients with schizophrenia.
For this study, patients with schizophrenia with auditory verbal hallucinations who had inadequate response to at least 1 antipsychotic drug were recruited.
Investigators evaluated data collected for a population-based study of nearly 1.5 million adults that was conducted at seven sites across Australia.